Goldman Sachs initiated coverage of Sotera Health with a Buy rating and $20 price target. Sotera is a provider of sterilization and lab testing services, serving 40 of the top 50 medical device companies and 9 of the top 10 pharma companies globally, the analyst tells investors in a research note. Goldman cites Sotera's "durable" business model, high margin profile, and improving clarity around the financial impact of the Ethylene Oxide litigation for the Buy rating.
